291 related articles for article (PubMed ID: 33169789)
1. Cytotoxic T-lymphocyte elicited therapeutic vaccine candidate targeting cancer against MAGE-A11 carcinogenic protein.
Kumar N; Sood D; Gupta A; Jha NK; Jain P; Chandra R
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33169789
[TBL] [Abstract][Full Text] [Related]
2.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
3. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
4. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
5. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
[TBL] [Abstract][Full Text] [Related]
7. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
[TBL] [Abstract][Full Text] [Related]
8. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
11. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
12. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
13. The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.
Shi RR; Liu J; Zou Z; Qi YM; Zhai MX; Zhai WJ; Gao YF
Cancer Immunol Immunother; 2013 Nov; 62(11):1723-32. PubMed ID: 24077852
[TBL] [Abstract][Full Text] [Related]
14. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.
Herrera LRM
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858
[TBL] [Abstract][Full Text] [Related]
15. Excavating chikungunya genome to design B and T cell multi-epitope subunit vaccine using comprehensive immunoinformatics approach to control chikungunya infection.
Narula A; Pandey RK; Khatoon N; Mishra A; Prajapati VK
Infect Genet Evol; 2018 Jul; 61():4-15. PubMed ID: 29535024
[TBL] [Abstract][Full Text] [Related]
16. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
17. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
19. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]